Letters, Testimony & Filings Letter to the FDA Opposing Approval of Daprodustat and Other Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors December 14, 2022
Letters, Testimony & Filings Testimony Before the FDA’s Cardiovascular and Renal Drugs Advisory Committee Regarding Omecamtiv Mecarbil For the Treatment of Heart Failure December 13, 2022
Outrage of the Month: Congress Reauthorizes FDA-Corrupting User Fees for Five More Years December 1, 2022
Comments on the FDA’s Proposed Rule Regarding Nonprescription Drug Products With an Additional Condition for Nonprescription Use November 25, 2022
Letters, Testimony & Filings Follow-up Comments to the FDA Regarding CDER’s Proposal to Withdraw Approval of Makena (Hydroxyprogesterone Caproate) November 2, 2022